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Abstract
In individuals with cerebral palsy (CP), smaller muscle and atrophy are present at young age. Many people with CP also
experience a decline in gross motor function as they age, which might be explained by the loss of muscle mass. The clinical
observation of muscle wasting has prompted a comparison with sarcopenia in older adults, and the term accelerated
musculoskeletal ageing is often used to describe the hallmark phenotype of CP through the lifespan. However, there has been
very little research emphasis on the natural history of ageing with CP and even less with respect to the determinants or
prevention of muscle loss with CP.
Considering the burgeoning interest in the science of muscle preservation, this paper aims to (i) describe the characteristics of
accelerated musculoskeletal ageing in people with CP, (ii) describe the pathophysiology of sarcopenia and parallels with CP,
and (iii) discuss possible therapeutic approaches, based on established approaches for sarcopenia.
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Introduction
Cerebral palsy (CP) is the most common paediatric-onset
physical disability, with a prevalence of 1.7–3.1 per 1000
livebirths in high-income countries and higher prevalence in
low-income countries.1,2 Cerebral palsy is caused by an insult
to or malformation of the developing brain that affects
motor control centres and leads to alterations in growth
and development. Although the brain lesion that causes
CP is non-progressive, it affects overall health and especially
mobility throughout the lifespan.3,4 Following the central ner-
vous system lesion, the damage to the descending pathways
causes paresis—a reduction or failure of voluntary activation
and muscle over activity that can be described as spasticity,
spastic dystonia, and spastic co-contraction. Although the
primary brain lesion is static, these neural changes result in
a cascade of secondary musculoskeletal complications that
are progressive, including soft tissue contracture and bone
deformity.5,6 Research pertaining to the structure and physi-
ology of skeletal muscle of children and young adults with
CP has highlighted several abnormalities. In vivo studies of
muscle in ambulant individuals with CP report structural
differences between CP and typically developed (TD) muscle
including reduced muscle size7–10 and abnormal proportions
of contractile and non-contractile tissue.11–13 While loss of
muscle mass and function is apparent at higher ages in the
general population, smaller muscle and early atrophy are
already present at young age in individuals with CP.14,15
Individual differences determine the extent to which this im-
pacts physical performance, mobility, and functional ability.
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In fact, approximately 75% of the individuals with CP
who were once mobile eventually stop ambulating.16 It is also
well documented that even high-functioning children with CP
are at increased risk to lose ambulatory skills or turn to
assistive devices in adulthood,17 which leads to substantial
declines in functional skills, activities of daily living and/or
mobility, and independence.18–21 These clinical observations
have prompted a comparison with older adults without CP,
and the term ‘accelerated musculoskeletal ageing’ has been
proposed to describe the hallmark phenotype of CP
through lifespan.22 However, there has been very little
research emphasis on the natural history of ageing with CP
and even less with respect to the determinants or prevention
of muscle loss in CP.
In an attempt to stimulate research pertaining to clinically
observed, age-related muscle atrophy and weakness, the
term ‘sarcopenia’ was ﬁrst introduced in 1989.23 Despite
the exponential growth in this area of research over the past
30 years,24 there have been substantial obstacles with
adopting a consensus deﬁnition for the diagnosis of
sarcopenia in clinical settings. Although the initial deﬁnition
of sarcopenia was limited to describing age-related muscle
atrophy, muscle loss can also occur with disuse, chronic
inﬂammation, and inadequate macronutrient and micronutri-
ent intake or is associated with acute and chronic disease, all
of which are not necessarily age related.25,26 Therefore, the
term (primary) sarcopenia indicates muscle wasting related
to ageing, while ‘secondary sarcopenia’ refers to muscle loss
related to disuse, inﬂammation, or malnutrition.25 In the
elderly, however, the aetiology of sarcopenia can be multifac-
torial so the distinction between ‘primary and secondary
sarcopenia’ can be difﬁcult to make.25
Considering the burgeoning interest in the science of
muscle preservation in individuals with CP, it is time to con-
sider the knowledge and evidence related to sarcopenia in
the general population as it pertains to people with CP. This
paper aims to (i) describe the characteristics of accelerated
musculoskeletal ageing in people with CP, (ii) describe the
pathophysiology of sarcopenia and parallels with CP, and
(iii) discuss possible therapeutic approaches—what can we
learn from approaches in sarcopenia prevention/treatment?
Characteristics of muscle and muscle
growth in people with cerebral palsy: is
cerebral palsy characterized by
accelerated musculoskeletal ageing?
In 2010, the European sarcopenia consensus deﬁnition was
published,25 which (re)deﬁned sarcopenia as a condition in
which at least two of these three criteria apply: (i) low muscle
mass, (ii) low muscle strength, and/or (iii) low physical
performance. In this paragraph, we discuss characteristics of
muscle and muscle growth in people with CP and examine
whether the criteria of sarcopenia can also be applied to
individuals with CP.
Muscle size and composition
Muscle size (e.g. cross-sectional area or volume) are impor-
tant morphological properties and indicators of muscle
force-producing capacity,27 as well as insight into the amount
of metabolically active lean tissue available for glucose
storage and metabolism.28 In individuals with CP, the muscles
in the impaired limb are smaller than the muscles in the
unimpaired limb, and both are smaller compared with a mus-
cle of a TD child.7 Cross-sectional studies investigating muscle
volume in individuals with CP and TD peers report differences
in muscle size that are evident early in development, with as
much as 22% smaller calf muscle size in children with CP
present by preschool age.29 The differences in muscle volume
of ambulant individuals with CP compared with TD peers in-
crease with age to over 45% smaller calf muscle size in young
adults with CP.22 In individuals with unilateral CP, the often
considered ‘unaffected limb’ has muscle that is more similar
to the impaired limb with smaller volume and altered muscle
quality compared with TD peers.30 Muscle size differences
between individuals with CP and TD peers have also been
reported for the volume of nine large lower-limb muscles in
adolescents and cross-sectional area of the psoas muscle
in adults.8,31 Among adults, a previous study using computed
tomography demonstrated that the psoas muscle in CP is
signiﬁcantly smaller and less dense, indicating greater muscle
fat inﬁltration and lower muscle quality.32
Muscle is composed of contractile and non-contractile
tissues. The contractile tissue is the force-generating
tissue that causes movement. It is composed of sarcomeres,
the building blocks that form muscle ﬁbres, and bundles of
muscle ﬁbres that form fascicles. The contractile tissue is
highly metabolic. The non-contractile tissue comprises
predominantly connective tissue in series (i.e. tendons) and
parallel (aponeuroses and muscle cell framework), as well
as intermuscular and intramuscular fat. Muscles of the lower
limb of individuals with CP have greater connective tissue
fraction12 and more intermuscular and intramuscular fat on
magnetic resonance imaging and computed tomography
and have altered echo intensity parameters, indicative of
increased non-contractile tissue, on B-mode ultrasound
compared with TD peers.11,13,30,33 Therefore, the proportion
of muscle volume that includes the contractile tissue
may be less. Ex vivo studies of muscle from ambulant and
non-ambulant children with CP compared with TD children
further report reduced myoﬁbre cross-sectional area,34
altered ﬁbre type distribution,35 shorter and stiffer muscle
cells,36 and longer and fewer sarcomere in series.37
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Reduced muscle volume with greater connective tissue
and fatty inﬁltration in individuals with CP greatly
reduces the force generation capacity of muscle31 and
also reduces the pool of metabolic lean tissue compared with
TD individuals. Moreover, altered muscle ﬁbre and sarcomere
structure further reduces the force and movement generat-
ing capabilities. To date, no studies have quantiﬁed muscle
structure and composition of the upper limb in individuals
with CP or investigated the muscle changes throughout
adulthood with CP.
Muscle growth
There is limited published information describing muscle
growth in individuals with CP. To date, there has been only
one longitudinal study describing the growth of lower-limb
muscle in children with CP.15 It was shown that in pre-
school-aged children with CP, growth of the calf muscle was
signiﬁcant at 12 months follow-up, even after lower-limb bot-
ulinum toxin treatment (an established treatment to reduce
muscular hyperactivity due to spasticity in children and adults
with CP). However, the overall muscle growth of the spastic
muscle in children with CP over 12 months was 60% lower
than in TD peers. Recent cross-sectional studies report calf
muscle volume increases linearly with age in CP; however,
the muscle volume increased to a lesser extent than in TD
children.10,14 In a combined group of children with unilateral
and bilateral CP, muscle growth, as indicated by the slope of
the age–volume relationship, was almost half that of TD chil-
dren.14 Moreover, the muscles of children with unilateral CP
developed at a slower rate than the muscles of children with
bilateral CP, with muscle growth at 23% and 65% of the TD
muscle growth rate, respectively.10 The lower muscle growth
rate results in a greater disparity of calf muscle volumes be-
tween the CP groups as children progress into adolescence
and adulthood.
The limited research investigating muscle growth in indi-
viduals with CP has focused on the early childhood years. This
period often includes standard care treatments that aim to
reduce spasticity and slow contracture development and
maintain walking ability in these children.38 Treatments
including serial casting and intramuscular botulinum toxin in-
jections may also compromise muscle growth.39–41 However,
current studies have not differentiated between the effects
of treatments and the underlying mechanisms that lead to re-
duced growth in CP in general, as compared with TD children.
Surgical interventions for lower-limb soft tissue contracture
reduce muscle growth, but muscle volume was found to
recover 1 year after surgery.42
The natural history of muscle growth and decline with age
in individuals with CP remains unknown. Moreover, the
speciﬁc reasons for reduced longitudinal muscle growth,
development of contractures, and peripheral factors
responsible for muscular weakness also remain poorly
understood. It is plausible that this may stem from the brain
lesion causing CP, with the impact of reducing total muscle ﬁ-
bre number in an impaired muscle.43 Furthermore, genetic
alterations have been identiﬁed in spastic CP muscle, which
give rise to competing pathways for muscle hypertrophy
and decrease in anabolic growth factors. The efﬁciency of
protein uptake and synthesis (among other building
processes) remains unknown in CP.
Strength and function
Structural abnormalities in the muscle among individuals
with CP, including reduced muscle size and abnormal
composition, combined with altered neural control (e.g.
increased co-contraction and selective activation44,45), con-
tribute to reduced muscle strength and power compared
with TD individuals.31,46–48 Muscle strength varies widely
not only among individuals but also among disability severity,
as classiﬁed by the Gross Motor Function Classiﬁcation
System (GMFCS; function deteriorates from levels I to V).49
The muscle strength of children classiﬁed as GMFCS levels I
and II ranges between 50% and 100% of predicted normal
for all muscle groups of the lower extremity except ankle
dorsiﬂexors (which is lower). For children classiﬁed as GMFCS
level III, muscle strength is less than 50% of predicted normal
for all muscle groups of the lower extremity except knee
extensors (which is higher).50
While loss of muscle mass and function is expected in the
general ageing population, gradual loss of physical perfor-
mance and functional ability is present even at young ages
in individuals with CP. Hanna et al.51 showed that stability
of the gross motor function trajectories varies over time
when children and adolescents with CP transition into young
adulthood. In children classiﬁed as GMFCS levels III–V, the
average gross motor function score peaks before it declines
when children become adolescents and young adults. These
ﬁndings indicate that adolescents classiﬁed as GMFCS levels
III–V are at risk of losing motor function and physical
performance. Throughout adulthood, a gradual decline in
functional ability is reported across all GMFCS levels.52
Approximately 75% of individuals with CP included in the
study by Murphy et al.16 who were once mobile eventually
stopped ambulating. Adolescents with CP enter adult life
with reduced strength and functional reserve, with one-third
of adults with CP experiencing a decline in walking ability
before the age of 35 years.18 It is also well documented that
even high-functioning children with CP are at increased risk
to lose ambulatory skills or turn to assistive devices in
adulthood,17 which leads to substantial declines in functional
skills, activities of daily living and/or mobility,19 and
ultimately a loss of independence.18–21
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In children and young adults with CP, lower-limb muscle
strength is closely related to independent mobility with
muscle adaptations resulting in reduced walking speed and
distance, as well as more frequent tripping and falling.4,16
The reduced trajectory of muscle strength through develop-
ment may be the critical factor that determines functional
capacity and mobility in CP.22
The pathophysiology of sarcopenia: a
multifactorial concept caused by a
combination of interrelated factors
Several factors underlie the loss of muscle mass and function
with advanced age in TD individuals, such as anabolic
resistance, impaired muscle quality, and nutritional factors.
This section describes these factors in sarcopenia and
analogues what is known in people with CP.
Anabolic resistance and contributing factors like
inactivity, inﬂammation, and oxidative stress
Muscle mass is the result of a balance between continuous
synthesis and degradation of skeletal muscle proteins. Net
protein balance is deﬁned as the difference between skeletal
muscle protein synthesis (MPS) and breakdown (MPB). A
positive net protein balance (i.e. when MPS exceeds MPB)
can result in the accretion of skeletal muscle proteins
(anabolism). Conversely, a negative net protein balance (i.e.
MPB exceeds MPS) will result in a loss of skeletal muscle pro-
tein (catabolism). During the ageing process, protein turnover
declines,53 and a blunted response of MPS to anabolic stimuli
in a meal has been reported.54 This so-called anabolic
resistance is suggested as the major contributor to loss of
muscle mass in TD adults and elderly.55 Several factors can
contribute to anabolic resistance, such as inactivity, chronic
inﬂammation (inﬂammaging), and oxidative stress.56,57
Indeed, a more sedentary lifestyle plays an important role
in the development of sarcopenia.58 However, ageing is also
characterized by an increased incidence of enforced bed-rest
periods, secondary to injury or disease. These periods of total
inactivity contribute directly to the sarcopenia process as it
has been shown that the rate of muscle mass loss is acceler-
ated in older persons undergoing a period of bed rest.59
Disuse atrophy is characterized by a reduction in muscle ﬁbre
cross-sectional area. The consequences of inactivity-induced
muscle wasting include reduced strength and muscle quality,
with deleterious effects on quality of life and independence
in daily activities. Furthermore, this reduction in metaboli-
cally active lean tissue results in decreased capacities of
whole-body glucose storage and metabolism,28,60 which
contributes to insulin resistance, and a lower whole-body
metabolic rate.61 Muscle disuse has been studied after a
variety of interventions including bed rest, casting, limb sus-
pension, and spaceﬂight. Whenever human MPS has been
measured after inactivity, a marked decline has been
observed in 24 h MPS, because of lowered fasted MPS and
a reduced postprandial MPS response to an anabolic stimu-
lus. The reduced MPS occurs relatively early in immobilization
(within 10 days of bed rest) and does not decline further.59
Thus, anabolic resistance is not always age related. It can also
be a direct consequence of disuse and deconditioning. In
young adults who have been typically developing, a reduction
in physical activity through cast-induced immobilization of
the legs blunts basal and amino-acid stimulated rates of
MPS.62–64 Thus, it is apparent that disuse induces anabolic
resistance in skeletal muscle regardless of age. Recent work
also indicates that even short-term abrupt sedentary behav-
iour, leading to a reduced relative loading of skeletal muscles,
resulted in loss of muscle mass in the legs.65
In addition, oxidative stress and chronic inﬂammation play
important roles in muscle atrophy.66 The interaction of these
factors affects the balance between MPS and MPB, inducing
skeletal muscle cell death (apoptosis), which leads to signiﬁ-
cant loss of muscle mass. The state of oxidative stress seems
to trigger the pathogenesis of muscle wasting in chronic
diseases.67 The deleterious effect of oxidative stress on the
muscle can also be explained through its participation to
the low-grade inﬂammation status by triggering the release
of inﬂammatory cytokines or by participating to the reduced
sensitivity of muscle to leucine anabolic action.68 Elevated
levels of low-grade inﬂammation induced by oxidative stress
are detrimental to skeletal muscle in humans,69 as well as
in animal models.70 Age-related low-grade inﬂammation has
been associated with a decrease in muscle mass and
strength71 and a loss of physical function.72
Analogue cerebral palsy
To the best of our knowledge, there are currently no studies
that have examined anabolic resistance in people with CP.
However, children with CP have one of the most sedentary
lifestyles across paediatric disabilities.73 From 2 to 3 years
of age, children with CP show signiﬁcantly more sedentary
behaviour than TD children and, not surprisingly, GMFCS level
correlates with sedentary behaviour, with more sedentary
behaviour occurring in those with levels IV and V.74
Decreased activity levels not only lead to muscle weakness,
disuse muscle atrophy, and muscle shortening but also lead
to further activity limitations, which prompt a vicious circle
of inactivity and disuse.75 Despite the lack of studies to di-
rectly measure anabolic response in children with CP, the
low physical activity levels and related disuse make it plausi-
ble that children with CP have decreased anabolic responses
to dietary amino acids and protein, to a similar extent seen in
the elderly with sarcopenia.
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In children with CP, oxidative stress may be caused by a
deﬁciency in vitamin and food intake, environmental factors
(i.e. passive smoking and fruit juice intake), and epileptic
seizures.76 However, the few studies that have examined
oxidative stress markers in children with CP have yielded in-
conclusive ﬁndings. Aycicek and Iscan76 showed that children
with CP have increased lipid hydroperoxide levels (a marker
for oxidative stress) and decreased antioxidant levels when
compared with TD children. The authors concluded that
children with CP have an impaired oxidative/antioxidative
balance when compared with TD children. In contrast, Kulak
et al.77 showed that children with CP have similar lipid
hydroperoxide levels as TD children. At the same time, some
antioxidant enzyme levels were found to be lower in children
with CP, whereas other antioxidant enzyme levels were
higher, which led the authors to conclude that children with
CP do not show elevated levels of oxidative stress compared
with their TD peers.
Impaired muscle quality, that is, muscle strength
per mass unit, and muscle function with underlying
factors like intramuscular fat, impaired
mitochondrial function, muscle ﬁbre type changes,
and neuromuscular innervation
Apart from the decrease in muscle mass, which is reﬂected by
a decrease of up to 50% in the size and number of muscle ﬁ-
bres from 20 to 90 years of age,78 there are also composition
changes in the muscle that occur with age. Speciﬁcally, there
is a selective age-related atrophy of type 2 ﬁbres (glycolytic
ﬁbres, predominant in fast-twitch muscles).79 Moreover,
there is an age-dependent increase in muscle fat content,
which is known to be positively correlated with whole-body
fat.80 Age-related muscle fat inﬁltration can be part of the
sarcopenia process, as it is associated with lower muscle
strength81 and an increased risk of developing mobility limi-
tations.82 Moreover, speciﬁc loss of α-motor neurons83 leads
to multiple processes of denervation–renervation of muscle
ﬁbres and consequently to the decline in coordinated
muscle action and reduction in muscle strength. Another
factor in the pathogenesis of sarcopenia is the age-related
decrease in mitochondria number and function. This is the
consequence of an alteration in the expression of genes
encoding mitochondria protein,84 a decrease in mitochondria
protein synthesis,85 a decrease in mitochondria oxidative
capacity, and ATP production rates.84 This can have a major
impact on endurance capacity and muscle fatigue, which in
turn can contribute to the decreased physical function ob-
served in elderly. A new study suggests that mitochondrial
dysfunction, reduced insulin sensitivity, and reduced physical
endurance are related, at least in part, to physical inactivity
and to increases in adiposity rather than to ageing alone.86
Analogue cerebral palsy
Muscles of the lower limb of ambulant individuals with CP
have greater connective tissue fraction12 and more
intermuscular and intramuscular fat11,13,33,87 compared with
TD peers. Furthermore, Johnson et al.13 showed that children
with quadriplegic CP (GMFCS III–V) had 2.3-fold higher
intermuscular adipose tissue in the mid-thigh muscles than
control subjects, and this was related to their low levels of
physical activity. At a muscle ﬁbre level, Ito et al.88 showed
a type 1 ﬁbre predominance in spastic muscles of individuals
with CP and a type 2b ﬁbre deﬁciency with signiﬁcant varia-
tion in ﬁbre size. It is also reported that spastic muscle in
CP show myoﬁbrillar disorganization in poorly deﬁned
areas (moth-eaten ﬁbres), ﬁbres with rounded contours
in cross section (vs. normal polygonal contours), and in
some cases, an increased extracellular matrix and ﬁbrotic
increase in passive stiffness.43 Taken together, these studies
show that children with CP have lower muscle quality than
TD children, which might contribute to impaired muscle
function in this particular patient group.
Nutritional factors: deﬁciencies of protein and
vitamin D
Although older adults may decrease their overall energy
intake, the actual need for certain macronutrients and
micronutrients may increase with age. Inadequate nutrition
or malabsorption and/or maldigestion are suggested as one
of the underlying mechanisms involved in the onset or
progression of sarcopenia.25 Certain nutrients are referred
to as musculoskeletal nutrients, that is, protein, calcium,
vitamin D, magnesium, and phosphorus.89 The relation
between nutrients and muscle parameters has been exten-
sively reviewed by Mithal et al.90 for protein, vitamin D,
and the B vitamins and by Robinson et al.91 for antioxidants
and long-chain polyunsaturated fatty acids. However,
nutritional recommendations for sarcopenia mainly apply to
consideration of adequate protein intake and adequate
vitamin D status,92 as the evidence for these nutrients is most
evident. Considering the role of malnutrition in the
pathophysiology of sarcopenia,25 adequate energy intake is
important to prevent muscle loss.
Adequate protein intake is especially relevant for
stimulation of MPS in conditions of anabolic resistance. This
is intuitive, as muscle is the largest protein reservoir in the
body, with muscle proteins being replaced at a rate of 1–2%
per day. A dietary intake study in a large cohort showed that
protein intake decreases with age.93 High daily protein intake
in healthy older adults is associated with a reduced loss of
muscle mass, as shown in several cohort studies in older
people.94 Indeed, individuals with sarcopenia showed a
lower intake of dietary protein compared with non-
sarcopenic individuals.95,96 Among 55- to 77-year-old
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ambulatory men and women, 14 days of controlled dietary
protein intake at the recommended level (recommended
dietary allowance: 0.8 g protein/kg body weight (bw)/day)
resulted in a signiﬁcant decrease of the mid-thigh muscle
area and a decrease in urinary nitrogen excretion.97 This also
implies that a protein intake greater than the recommended
dietary allowance in elderly is required to maintain nitrogen
balance, fat-free mass, and muscle mass.97 Explorative stud-
ies suggest that healthy older people may require a minimum
protein intake of 1.0 to 1.5 g/kg bw/day to achieve a null
nitrogen balance and to preserve muscle mass, strength,
and function.98 A recent consensus paper by the dietary
protein needs with ageing group advised that older adults
should consume 1.0–1.2 g protein/kg bw/day, and even
higher amounts are recommended for older adults who are
malnourished.99
Moreover, protein intake varies throughout the day. This is
important as it is hypothesized that 25–30 g high-quality
protein per meal is needed for adequate stimulation of MPS
to counteract anabolic resistance with ageing.100 Habitual
protein intake is highest at lunch or evening meals but is
especially low at breakfast.101–104 The habitual low-protein
intake at breakfast may therefore prevent maximal MPS.
One recent publication indicated that the distribution of pro-
tein intake over the day differs between frail and non-frail
community-dwelling seniors, with the lowest intake at break-
fast in the frail.105
The lack of speciﬁc (anabolic) nutrients is responsible for
the loss of muscle mass; however, an adequate caloric intake
is also needed to facilitate metabolic processes. If nutrients
intake is insufﬁcient to meet the needs, resulting in malnutri-
tion, body fat and muscle will be catabolized to provide en-
ergy.106 Therefore, meeting the daily energy
recommendation is important for the maintenance of muscle
mass and physical performance.
Age-related declines in vitamin D receptor can also
contribute to the loss of muscle strength.107 The importance
of adequate vitamin D status is recognized, but low serum vi-
tamin D levels are also commonly reported. Houston et al.94
reported inadequate levels (<50 nmol/L 25(OH)D) in 75% of
older women and 50% of older men (InCHIANTI cohort).
The vitamin D intake through nutrition was found to be low
in elderly in Europe,108 and inadequate vitamin D intake is
indeed a health concern. Also, the reduced time spent
outdoors and the skin’s decreased ability to make vitamin D
contribute to low vitamin D status with ageing. Several
observational studies found an association between vitamin
D status and muscle strength, physical performance (e.g. bal-
ance and chair stand), physical activity, fall occurrence, and
activities of daily living.109,110 Describing the exact working
mechanism of vitamin D and its receptor in muscle is outside
the scope of this review (for a review on this topic, see
Hamilton, 2009111). In short, vitamin D is involved in the tran-
scription of a range of proteins, including those involved in
calcium metabolism, which is critical for skeletal muscle
function. It is also widely believed that vitamin D has a rapid
effect on membrane calcium channels thereby being a critical
modulator of muscle function.111 Another mechanism by
which vitamin D acts on muscle is through increasing the
sensitivity of MPS to an anabolic stimulus, as shown for
leucine in muscle cells under vitamin D-deﬁcient and vitamin
D-supplemented conditions.112 Vitamin D thus seems essen-
tial for muscle function.
Analogue cerebral palsy
Some of the nutritional factors that contribute to the devel-
opment of sarcopenia might also play a role in the muscle
function of people with CP. The prevalence of malnutrition,
which may result in an inadequate protein intake, is also
elevated in the CP population.113 Adequate dietary protein
intake may therefore be a critical key factor for maintaining
skeletal muscle mass in people with CP. This is supported
by the ﬁndings of Arrowsmith et al.114 who found low total
body protein levels (as measured by neutron activation anal-
ysis) in children with spastic quadriplegic CP. This could be
the result of reduced muscle mass due to inactivity, or,
malnutrition coupled with the inactivity and consequently
decrement in muscle volume. There are many possible
reasons people with CP fail to consume enough protein to
meet their needs. Medical conditions (food processing and
swallowing problems), physical and mental disabilities that
limit shopping and food preparation, and food insecurity
due to ﬁnancial and social limitations are commonly reported
reasons.113
Despite the feeding and swallowing difﬁculties in a great
proportion of the children with CP, different studies showed
no differences in protein intake between children with CP
and their TD peers.115–118 However, to date, it remains
unclear whether children with CP have similar protein
requirements as TD children. Many people with CP
participate in intensive (strengthening) exercise programmes,
and because exercise causes muscle micro-damage, it is
important to replace and rebuild this tissue to allow for
hypertrophy and strength increases.119 Therefore, it may be
argued that for children with CP, it is crucial that a regular
dietary intake of high-quality proteins is necessary and that
there is even a higher need for these proteins than for
children without CP.
Adequate vitamin D intake is essential for preservation of
muscle strength and function. Individuals with CP may be at
heightened risk for hypovitaminosis D-induced osteopenia
and impaired bone mass accrual. The risk of secondary health
complications associated with or exaggerated by the combi-
nation of insufﬁcient vitamin D, chronic sedentary behaviour,
and obesity may also be higher. Indeed, about 30% of the
children with CP have insufﬁcient vitamin D status120,121;
however, a major difﬁculty in comparing literature on this
topic is the use of different cut-off points for vitamin D
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deﬁciency. Therefore, it is difﬁcult to say whether the
percentages in CP are high or similar compared with the
general population in which a deﬁciency prevalence of
2–60% is reported.122,123 Although present across all GMFCS
levels, vitamin D deﬁciency is more prominent in children
classiﬁed at GMFCS levels IV and V, who might have reduced
outdoor activity. One of the factors that could contribute to
vitamin D deﬁciency is the use of anticonvulsants.124
About 41% of children with CP have epilepsy, and anticonvul-
sant use is common. It can therefore be assumed that vitamin
D deﬁciency is common in this population. Moreover, in a
recent study with CP adults, more than 50% were either vita-
min D insufﬁcient or deﬁcient, and abdominal adiposity was a
strong independent predictor for low vitamin D levels.125
Therapeutic approaches in sarcopenia
with focus on (i) protein (quantity per
day and at each meal; protein quality),
(ii) vitamin D, and (iii) combination
with exercise
Recommending dietary modiﬁcations, nutritional supple-
ments, and exercise therapy separately or in combination
can be appropriate steps to stimulate muscle growth and
combat muscle deterioration in people with CP. Maximizing
muscle mass can improve functionality, strength, endurance,
and general metabolic health. Based on the pathophysiology
of sarcopenia and prevalent nutritional deﬁciencies,
therapeutic approaches with protein, vitamin D, and/or
exercise have been applied. This section discusses what we
can learn from these approaches for possible future interven-
tions in individuals with CP.
Protein interventions
It is well established that dietary protein ingestion stimulates
skeletal MPS and inhibits protein breakdown, resulting in a
positive protein balance and net muscle mass gain.126,127
Net protein balance is maintained by ingestion of
protein-containing meals, which results in systemic
hyperaminoacidaemia that is stimulatory for the synthesis
of new proteins.128–130 The ingested protein dose and source
dictates the amplitude and duration of the rise in essential
amino acids in the blood, which, in turn, affects the degree
of MPS.126,131 In addition to increasing the total dose of
protein or (essential) amino acids in a meal,132 a diminished
anabolic responsiveness with ageing can be overcome by
increasing the proportion of the amino acid leucine,133 espe-
cially at low-protein intake.134 Only one study measuring MPS
was performed in sarcopenic older adults and demonstrated
an increase of MPS after a leucine-enriched whey protein
supplement.135
Vitamin D
While the recommendations for older sarcopenic adults
are in favour of vitamin D supplementation, randomized
controlled trials (RCTs) on muscle strength show non-conclu-
sive results. Both positive effects136–138 and absence of
effects139–141 were observed with vitamin D supplementa-
tion. These contradictory results may be attributed to the
differences in study design, for instance, baseline vitamin D
levels, vitamin D dosing schedule (daily, weekly, or monthly),
the dosage of vitamin D supplemented, or the duration of the
intervention. Supplementation of at least 800 IU (20 μg)
showed, however, an effect on muscle strength.136,137 The ev-
idence to support vitamin D supplementation for falls and
fracture prevention is more apparent, indicating a beneﬁcial
effect of vitamin D supplementation.142,143 Based on ﬁve
RCTs involving 1237 participants, Bischoff-Ferrari et al.109
concluded that vitamin D supplementation appears to reduce
the odds of falling by 22% compared with patients receiving
calcium supplements or placebo. It has been suggested that
this beneﬁcial effect of vitamin D on falling could be ex-
plained by 1.25 hydroxyvitamin D binding to a highly speciﬁc
nuclear receptor in muscle tissue, leading to improved
muscle function and thereby reduced risk of falling. In a
2 month intervention of elderly ambulatory women, vitamin
D plus calcium supplementation improved body sway by 9%
when compared with calcium supplementation alone.144
Similarly, musculoskeletal function increased by 4–11% in
institutionalized elderly women after an intervention with
vitamin D and calcium compared with calcium alone. More-
over, the combination of adequate vitamin D and anabolic
leucine optimized the MPS response in vitamin D-deﬁcient
muscle cells.112 Along the same lines, sufﬁcient baseline
25(OH)D levels and protein intake may be required to
increase muscle mass as a result of an intervention with a vi-
tamin D and protein supplement in sarcopenic older adults.96
Exercise
The synergistic effect of protein ingestion with exercise
potentiates the muscle synthetic response, swinging net
balance in favour of muscle protein accretion,145 thereby
permitting muscle hypertrophy when practised frequently
over time.146 Regular exercise may also help normalize some
aspects of age-related mitochondrial dysfunction and, in turn,
improve muscle function.86
Exercise is known to improve muscle strength and function
in both the young and the elderly. An updated meta-analysis
by Sherrington et al.147 showed that exercise as a single
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intervention can prevent falls in community-dwelling older
people. In particular, exercise programmes that challenge
balance and are of a high intensity have larger effects. It thus
seems that exercise alone can already help preventing falls in
(healthy) elderly. However, it is also known that protein
ingestion after a single bout of resistance-type exercise
stimulates muscle protein accretion during post-exercise
recovery. Nutrition in combination with exercise is
considered optimal for maintaining muscle function.148 Con-
sequently, it is believed that protein supplementation can
augment the effects of resistance-type exercise training.
Cermak et al.149 performed a systematic review to deﬁne
whether this is indeed the case. Based on 22 RCTs that
included 680 subjects, they concluded that protein
supplementation after prolonged (>6 weeks) resistance-type
exercise training has a positive effect on fat-free mass and
one repetition maximum leg press strength in younger
and older subjects. This suggests that a combination of
nutrition with exercise could be optimal for maintaining
muscle function.148
Analogue cerebral palsy
Although comparable nutritional intervention studies in
people with CP are lacking, a recent systematic review has
highlighted that there is preliminary evidence that strength
training leads to muscle hypertrophy in children and adoles-
cents with CP.48 However, nutritional supplementation in
combination with resistance training or a physical activity in-
tervention has not been investigated in people with CP.
Conclusions
In this review, we highlight the evidence for early and
accelerated musculoskeletal ageing in CP, which may be
comparable with sarcopenia among older adults without
CP. Given the fact that nutritional interventions (combined
with exercise training) have shown promising effects for
mitigating sarcopenia and improving muscle mass and
function, future studies should investigate the effect of these
interventions as a primary preventive strategy among individ-
uals with CP.
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